scholarly journals Recombinant Varicella-Zoster Virus Vaccines as Platforms for Expression of Foreign Antigens

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Wayne L. Gray
Keyword(s):  
Older Adults ◽  
Animal Models ◽  
Infectious Diseases ◽  
Varicella Zoster Virus ◽  
The Elderly ◽  
Recombinant Vaccines ◽  
Varicella Zoster

Varicella-zoster virus (VZV) vaccines induce immunity against childhood chickenpox and against shingles in older adults. The safety, efficacy, and widespread use of VZV vaccines suggest that they may also be effective as recombinant vaccines against other infectious diseases that affect the young and the elderly. The generation of recombinant VZV vaccines and their evaluation in animal models are reviewed. The potential advantages and limitations of recombinant VZV vaccines are addressed.

scholarly journals Varicella Zoster virus infection: immunity, diagnosis and modelling in vivo

2019 ◽  
pp. 82-89
Author(s):  
V. F. Lavrov ◽  
O. A. Svitich ◽  
A. S. Kazanova ◽  
A. R. Kinkulkina ◽  
V. V. Zverev
Keyword(s):  
Varicella Zoster Virus ◽  
The Elderly ◽  
Varicella Zoster Virus Infection ◽  
Viral Agent ◽  
Immune Protection ◽  
Varicella Zoster ◽  
Additional Information ◽  
Adaptive Mechanisms ◽  
Experimental Approaches

Varicella Zoster Virus (VZV) is a highly contagious viral agent of the Herpesviridae family, which has a strict species specificity, and causes two different diseases — chickenpox, mainly in children, and herpes zoster — more often in the elderly. Obtaining additional information about the life cycle of the virus, its biology, pathogenetic features of the complications caused by it, will contribute to the emergence of more advanced methods of diagnosis and prevention, the development of new experimental approaches that allow to study the innate and adaptive mechanisms of immune protection in VZV-infection.

Steroids and Varicella

PEDIATRICS ◽  
1993 ◽  
Vol 92 (2) ◽  
pp. 288-289
Author(s):  
NANCY A. REICHES ◽  
JAMES F. JONES
Keyword(s):  
Infectious Diseases ◽  
Varicella Zoster Virus ◽  
Low Dose ◽  
Retrospective Studies ◽  
Case Reports ◽  
Fatal Outcome ◽  
Adverse Outcomes ◽  
High Dose ◽  
Varicella Zoster ◽  
Immunosuppressed Patients

Reasons for adverse outcomes of infectious diseases are always under scrutiny. We expect infectious illnesses to have a specific course and outcome. Outcomes outside of the expected range are unacceptable, although the natural course of each infection includes them. Adverse outcomes that are products of medical invention are of particular import because they imply changes inpractice. One such situation is corticosteroid-induced fatal or severe varicella-zoster virus (VZV) infections. This topic, although not new, has received considerable interest because of recent warnings by the Food and Drug Administration.1 Case reports, retrospective studies, and reviews that have appeared since the 1950s suggest that high-dose (<1 to 2 mg/kg per day) but not low-dose (5 to 20 mg/day) systemic use of corticosteroids in both immunocompetent and particularly in immunosuppressed patients may be associated with severe or fatal outcome, particularly if the drugs are given immediately prior to or during the incubation period.

Sign in / Sign up

Export Citation Format

Share Document